TPG Capital has entered into a definitive agreement to acquire - Immucor, a provider of automated instrument-reagent systems for blood transfusion, for $1.973bn.
Immucor manufactures reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion.
Immucor shareholders will receive $27 in cash for each share of Immucor common stock they own, representing a premium of approximately 30.2% over the closing share price, as per the transcation.
Immucor president and CEO Joshua Levine said partnering with TPG allow them to continue with their commitment to deliver technologies that meet customers’ needs and improve patient safety.
TPG partner Todd Sisitsky said they look forward to work with the Immucor team as they invest in growing the business and expanding the global footprint for these vital services.